ONC to Congress: EHR adoption, meaningful use rising steadily
In its latest official report to Congress, the Office of the National Coordinator (ONC) praises the nation’s progress in health IT adoption, including EHR implementation and participation in the EHR Incentive Programs.
Iron dosing regimens affect dialysis patients’ infection risk
While intravenous iron is critical for maintaining the health of many dialysis patients, administering large doses over a short period of time increases patients’ risk of developing serious infections, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Smaller doses given for a longer period of time appears to be much safer, the study authors found.
Boehringer Ingelheim and Eli Lilly and Company have announced results of a 52week Phase III clinical trial of the investigational compound empagliflozin*, which showed statistically significant reductions in HbA1c (average blood glucose) at week 24, with the addition of empagliflozin to existing oral glucoselowering therapy in people with Type 2 Diabetes (T2D) and mild to moderate renal impairment as measured by the estimated glomerular filtration rate (eGFR ≥60 to <90mL/min/1.73m2 and eGFR ≥30 to <60mL/min/1.73 m2). Researchers make major advances in creating artificial pancreas
In a major advance in the development of an artificial pancreas, researchers have shown that an insulin pump can be programmed to temporarily shut off when blood glucose levels dip too low, successfully reducing the duration and incidence of nighttime hypoglycemia, according to study results published in the New England Journal of Medicine and presented concurrently at the American Diabetes Association’s 73rd Scientific Sessions.
Leave a Reply